Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Citius Pharmaceuticals Inc. Common

CTXR

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Last trade $0.5091
Day change -$0.0185 (-3.51%)
Day range $0.504 – $0.53
Volume 86,005
Market cap $14M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$14.55M
Price / earnings
—
Price / book
0.22×
Price / sales
2.05×
EV / sales
0.56×
EV / EBITDA
-0.06×

Profitability

Earnings per share
-$1.69
Return on assets
-32.53%
Return on equity
-69.47%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.1×
Current ratio
0.84×
Quick ratio
0.4×
Cash ratio
0.33×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$34.87M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CTXR, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$1.49M$1.67M$3.94M$0$0$0$0$0
Cost of revenue$491.84K$328.88K$789.21K$0$0$0$0$0
Gross profit$1M$1.34M$3.15M$0$0$0$0$0
Selling, general and administrative$9.96M$26.39M$10M-$4.04M$7.17M$4.79M$7.91M-$3.7M
Research and development$1.05M$3.35M$1.6M$1.64M$1.62M$3.77M$2.13M$2.91M
Total operating expenses$12.73M$33.53M$12.17M$8.44M$8.79M$11.26M$10.04M$11.05M
Operating income-$11.73M-$32.19M-$9.02M-$8.44M-$8.79M-$11.26M-$10.04M-$11.05M
Interest expense-$231.73K-$33.03K-$155.54K-$95.52K-$172.26K$0$0$0
Income before taxes-$12.03M-$28.34M-$9.13M-$8.48M-$8.94M-$11.25M-$10.02M-$10.93M
Income taxes-$107.35K-$231.21K$264.24K$264.24K$264.24K$264.24K$264.24K$144K
Net income-$11.92M-$28.11M-$9.39M-$8.74M-$9.2M-$11.51M-$10.28M-$11.08M
Net income attributable to common shareholders-$8.86M-$21.23M-$8.22M-$7.96M-$8.79M-$10.92M-$9.77M-$11.52M
EBITDA-$11.73M-$32.19M-$9.02M-$8.44M-$8.79M-$11.26M-$10.04M-$11.05M
Basic earnings per share-$0.34-$0.95-$0.38-$0.46-$0.80-$1.27-$1.30-$1.59
Diluted earnings per share-$0.34-$0.95-$0.38-$0.46-$0.80-$1.27-$1.30-$1.59

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Pharmaceuticals reported its first revenue of $3.9 million in Q1 2026 following the December 2025 launch of LYMPHIR by its majority-owned subsidiary Citius Oncology. The drug, approved for treating relapsed or refractory cutaneous T-cell lymphoma, has begun initial sales through a nationwide distributor network. The company raised $20.9 million in equity financing and is advancing late-stage pipeline candidates Mino-Lok and Halo-Lido while exploring international expansion and combination therapy opportunities.

Benzinga

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Oncology reported its first revenue of $3.9 million following the successful December 2025 U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company established nationwide distribution infrastructure and deployed an AI-enabled commercial platform. Despite positive commercial progress, the company reported a net loss of $5.5 million for Q1 2026 and held $7.3 million in cash as of December 31, 2025.

Benzinga

Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED)

U.S. stock futures declined slightly on Christmas Eve despite a strong Q3 GDP report showing 4.3% annualized growth. Major indices ended higher on Tuesday, with communication services, IT, and energy stocks leading gains. Several stocks gained attention: UiPath jumped 7% after joining the S&P Midcap 400, Citius Pharmaceuticals rose 8.65% on better-than-expected earnings, Ramaco Resources gained 8% after announcing a $100M buyback, and Multi Ways Holdings surged 62.86% on strong revenue growth.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 26, 20241-for-25reverse split
Jun 9, 20171-for-15reverse split